Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: A comparative study with FISH, SISH, and immunohistochemistry

Diagnostic Molecular Pathology

Volumn 17, Issue 4, 2008, Pages 220-226

  Capizzi, Elisa ^a   Gruppioni, Elisa ^a   Grigioni, Antonia D'Errico ^a   Gabusi, Elena ^a   Grassigli, Alberto ^b   Grigioni, Walter Franco ^a,c   Fiorentino, Michelangelo ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Istituto Oncologico Addarii   (Italy)

Author keywords

Breast cancer; FISH; HER 2; Immunohistochemistry; Real time PCR; SISH

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; PARAFFIN;

ADULT; AGED; ARTICLE; BREAST CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAMPLE; SENSITIVITY AND SPECIFICITY; SILVER IN SITU HYBRIDIZATION;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MIDDLE AGED; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY;

EID: 57649116288     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e318161f993     Document Type: Article

References (24)

1. Sant M, Francisci S, Capocaccia R, et al. Time trends of breast cancer survival in Europe in relation to incidence and mortality. Int J Cancer. 2006;119:2417-2422.
2. Ozols RF, Herbst RS, Colson YL, et al. American Society of Clinical Oncology: clinical cancer advances 2006: major research advances in cancer treatment, prevention, and screening - a report from the American Society of Clinical Oncology. J Clin Oncol. 2007;25:146-162.
3. Longo R, Torino F, Gasparini G. Targeted therapy of breast cancer. Curr Pharm Des. 2007;13:497-517.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
5. Bargmann CI, Hung MC, Weinberg RA. The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature. 1986;319:226-230.
6. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-182.
7. Pauletti G, Godolphin W, Press MF, et al. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene. 1996;13:63-72.
8. Wang S, Hossein Saboorian M, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol. 2002;15:137-145.
9. Ross JS, Fletcher JA, Bloom KJ, et al. HER-2/neu testing in breast cancer. Am J Clin Pathol. 2003;120:S53-S71.
10. Lewis F, Jackson P, Lane S, et al. Testing for HER2 in breast cancer. Histopathology. 2004;45:207-217.
11. Dietel M, Ellis IO, Höfler H, et al. Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists. Virchows Arch. 2007;451:19-25.
12. Schaller G, Evers K, Papadopoulos S, et al. Current use of HER2 tests. Ann Oncol. 2001;12:S97-S100.
13. Jacobs TW, Gown AM, Yaziji H, et al. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999;17:1983-1987.
14. Pauletti G, Dandekar S, Rong H, et al. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol. 2000;18:3651-3664.
15. Dendukuri N, Khetani K, McIsaac M, et al. Testing for HER2-positive breast cancer: a systematic review and cost-effectiveness analysis. CMAJ. 2007;176:1429-1434.
16. Bartlett J, Mallon E, Cooke T. The clinical evaluation of HER-2 status: which test to use? J Pathol. 2003;199:411-417.
17. Gjerdrum LM, Sorensen BS, Kjeldsen E, et al. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma: an alternative method for HER-2/neu analysis. J Mol Diagn. 2004;6:42-51.
18. Ginestier C, Charafe-Jauffret E, Penault-Llorca F, et al. Comparative multi-methodological measurement of ERBB2 status in breast cancer. J Pathol. 2004;202:286-298.
19. Vanden Bempt I, Vanhentenrijk V, Drijkoningen M, et al. Real-time reverse transcription-PCR and fluorescence in-situ hybridization are complementary to understand the mechanisms involved in HER-2/neu overexpression in human breast carcinomas. Histopathology. 2005;46:431-441.
20. Bossard C, Bieche I, Le Doussal V, et al. Real-time RT-PCR: a complementary method to detect HER-2 status in breast carcinoma. Anticancer Res. 2005;25:4679-4683.
21. Vinatzer U, Dampier B, Streubel B, et al. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization. Clin Cancer Res. 2005;11:8348-8357.
22. Wolff AC, Hammond ME, Schwartz JN, American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118-145.
23. -ΔΔCT method. Methods. 2001;25:402-408.
24. Selvarajan S, Bay BH, Choo A, et al. Effect of fixation period on HER2/neu gene amplification detected by fluorescence in situ hybridization in invasive breast carcinoma. J Histochem Cytochem. 2002;50:1693-1696.